TELESIS BIO (TBIO)
(Delayed Data from NSDQ)
$3.09 USD
+0.16 (5.46%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $3.16 +0.07 (2.27%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Telesis Bio Inc. [TBIO]
Reports for Purchase
Showing records 1 - 20 ( 108 total )
Company: Telesis Bio Inc.
Industry: Medical - Instruments
Company: Telesis Bio Inc.
Industry: Medical - Instruments
Life Science Earnings Recap: Three Groups of Opportunity Ahead, One Area of Risk (China)
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Telesis Bio Inc.
Industry: Medical - Instruments
Company: Telesis Bio Inc.
Industry: Medical - Instruments
2Q23 Above Consensus but Significant Ramp Ahead; Reduce from OW to SW
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Telesis Bio Inc.
Industry: Medical - Instruments
Path to Profitability on Track Despite Weak 1Q
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Telesis Bio Inc.
Industry: Medical - Instruments
Company: Telesis Bio Inc.
Industry: Medical - Instruments
4Q22 - Transformational Benchtop DNA Gaining Momentum
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Telesis Bio Inc.
Industry: Medical - Instruments
Positive Announcements Rolling Out at JPM
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Telesis Bio Inc.
Industry: Medical - Drugs
Company: Telesis Bio Inc.
Industry: Medical - Drugs
Company: Telesis Bio Inc.
Industry: Medical - Drugs
Company: Telesis Bio Inc.
Industry: Medical - Drugs
2Q21: Likely The Last Update Following Partner Sanofi''s Cash Offer
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Telesis Bio Inc.
Industry: Medical - Drugs
Company: Telesis Bio Inc.
Industry: Medical - Drugs
TBIO and Partner Sanofi In a Marriage, PT Decrease to $38, Rating Neutral
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Telesis Bio Inc.
Industry: Medical - Drugs
Company: Telesis Bio Inc.
Industry: Medical - Drugs
Are mRNA Companies Becoming the Most Highly Valued in Biopharma?
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Telesis Bio Inc.
Industry: Medical - Drugs
Preclinical Data from an mRNA Therapy Against Primary Ciliary Dyskinesia
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Telesis Bio Inc.
Industry: Medical - Drugs
Company: Telesis Bio Inc.
Industry: Medical - Drugs
mRNA Platform Continues to Look Forward, From MRT5005 and Beyond
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A